Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Microscopic polyangiitis


Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might microscopic polyangiitis (MPA) be treated?

The treatment of MPA is dependent on the extent of the disease, rate of progression, and the degree of inflammation. The goal of treatment is to stop organ damage that occurs as a result of MPA and involves use of medications that suppress the immune system. Treatment is typically carried out in three phases:[1][2][3]
  1. Remission induction using prednisone and cyclophosphamide. This phase usually lasts between 4 and 6 months. 
  2. Remission maintenance using prednisone and replacing cyclophosphamide with other medications such as methotrexate and azathioprine. This phases usually lasts between 12 and 24 months. 
  3. Treatment of relapse utilizing medications from phase one or other therapies such as intravenous immunoglobulin for resistant cases. 

Last updated: 7/6/2016

References
  1. Microscopic Polyangiitis. Cleveland Clinic Web site. 2/27/2014; http://my.clevelandclinic.org/health/diseases_conditions/hic_Microscopic_Polyangitis.
  2. Microscopic polyangiitis. The Johns Hopkins Vasculitis Center Web site. 2014; http://www.hopkinsvasculitis.org/types-vasculitis/microscopic-polyangiitis/.
  3. Farid-Moayer M. Microscopic polyangiitis. Medscape. December 21, 2014; http://emedicine.medscape.com/article/334024-overview.


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Microscopic polyangiitis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Rituximab
Trade Name
(Manufacturer Name)
Rituxan
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of pateints with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
More Information about this product Drug Information Portal
Medline Plus Health Information

Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.